Riociguat丨CAS 625115-55-1

Riociguat丨CAS 625115-55-1
Product Introduction:
Catalog No.: SS127205
CAS No.: 625115-55-1
Assay: 98%~102%
Product Name: Riociguat
Molecular Formula: C20H19FN8O2
Molecular Weight: 422.42
Send Inquiry
Technical Parameters
Description

Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of riociguat丨cas 625115-55-1 in China. Welcome to wholesale bulk high quality chemical products at competitive price from our factory. If you have any enquiry about custom service, please feel free to email us.

 

Specifications

 

Appearance: Off-white to white solid
Assay: 98%–102%
Identification: (1) The retention time of major peak in the chromatogram of the test solution corresponds to that of the reference solution
(2) 1H NMR spectrum is consistent with reference spectrum
(3) X-ray powder diffraction pattern (0°–40°): diffraction peaks at 6.7°±0.2°, 9.0°±0.2°, 14.3°±0.2°, 17.7°±0.2°, 25.5°±0.2° (crystal form I)
Related Substances: BA: 0.15% max
RG-8: 0.15% max
RG-7: 0.15% max
RG-10: 0.15% max
Unspecified impurity: 0.2% max
Total impurities: 0.5% max
Residual Solvent: Ethyl acetate: 0.5% max
Methanol: 0.3% max
Ethanol: 0.5% max
N,N-Dimethylformamide: 0.088% max
Dimethyl sulfoxide: 0.5% max
Water Content: 0.5% max

 

 

 

Applications

 

Riociguat (CAS 625115-55-1) is a pharmaceutical agent primarily used in the treatment of pulmonary hypertension, including pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It functions as a soluble guanylate cyclase (sGC) stimulator, enhancing the nitric oxide–cGMP pathway to induce vasodilation in pulmonary arteries. Riociguat is applied in oral formulations for chronic management of pulmonary hypertension, helping to improve exercise capacity, reduce pulmonary vascular resistance, and slow disease progression. It is also used in clinical research for exploring novel cardiovascular therapies targeting the sGC pathway.

 

Benefits

 

The benefits of Riociguat derive from its dual mechanism of action: direct stimulation of sGC and sensitization to endogenous nitric oxide. This results in effective vasodilation, improved pulmonary hemodynamics, and enhanced oxygen delivery to tissues. Riociguat has demonstrated clinical efficacy in increasing exercise tolerance, improving quality of life, and reducing hospitalization rates for patients with pulmonary hypertension. Additionally, its oral bioavailability and favorable pharmacokinetic profile enable convenient dosing and sustained therapeutic effects.

 

Conclusion

 

Riociguat is a targeted therapeutic agent for managing pulmonary hypertension, offering benefits through sGC stimulation and nitric oxide sensitization. Its efficacy in improving hemodynamics, exercise capacity, and patient outcomes makes it a valuable treatment in cardiovascular medicine. By addressing underlying vascular dysfunction, Riociguat remains an important compound in both clinical therapy and cardiovascular research.

 

 

Send Inquiry
Beyond Your Expectation
From Science to Life with LEAPChem
contact us